ArticlePloS one2023

Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19.

Matteo Ruggeri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.